Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Measurements

MS Mikaela Smit
AM Annalisa Marinosci
GN Giovanni Jacopo Nicoletti
TP Thomas Perneger
SR Silvio Ragozzino
DA Diego O Andrey
MS Marcel Stoeckle
FJ Frederique Jacquerioz
DL Dan Lebowitz
TA Thomas Agoritsas
BM Benjamin Meyer
HS Herve Spechbach
JS Julien Salamun
MB Moritz Back
CS Carla Schaubhut
SF Simon Fuchs
LD Laurent Decosterd
MB Manuel Battegay
IG Idris Guessous
FC François Chappuis
LK Laurent Kaiser
NL Niklaus D Labhardt
AC Alexandra Calmy
request Request a Protocol
ask Ask a question
Favorite

The following clinical definitions will be used. COVID-19 is defined as ≥1 symptom compatible with COVID-19 (cough, dyspnoea, anosmia, ageusia, elevated temperature (>38.0°C)) and either

a positive PCR for SARS-CoV-2 in oropharyngeal swab and/or

a seroconversion of IgG only or IgG and IgA for SARS-CoV-2 at day 21 in individuals with negative serology at baseline. In case of seroconversion of IgA only, seroconversion of IgG using more sensitive spike-based recombination immunofluorescence assay (S-rIFA) will be assessed.

New SARS-CoV-2 infection is defined as

a positive PCR for SARS-CoV-2 (oropharyngeal swab) among those with a negative PCR at baseline and/or

a seroconversion of IgG only or IgG and IgA for SARS-CoV-2 at day 21 in individuals with negative serology at baseline. In case of seroconversion of IgA only, seroconversion of IgG using more sensitive S-rIFA will be used.

Seroconversion for SARS-CoV-2 is defined as negative results for IgG in ELISA at baseline and either

positive result for IgG in ELISA and confirmation by S-rIFA at day 21 or

doubtful result for IgG in ELISA at day 21 and confirmation by S-rIFA. In case of negative result for IgG in ELISA at day 21 seroconversion can alternatively be defined as follows: Negative result of IgA in ELISA at baseline and (a) positive or doubtful result for IgA in ELISA at day 21 and (b) positive result for IgG in S-rIFA at day 21.

Copyright and License information:  ©2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A